ScientificReports journal published the results of the wide-genome analysis of DNA methylation of the breast tumor
ScientificReports (Q1, IF 3.998,) published an article being one of the first in the world, written by the researchers of the FSBI RCMG Epigenetics Laboratory (headed by V.V.Strelnikov, Doctor of biological sci.).
The purpose of pre-surgical (neoadjuvant) chemotherapy (NACT) is to reduce the tumor volume and the extent of surgical intervention. However, in 30-60% of cases, it does not lead to any expected response, and methods of predicting its effectiveness are still not efficient enough.
The FSBI RCMG Epigenetics Laboratory carried out a wide-genome analysis of DNA methylation and selected CpG dinucleotides, differential methylation of which discriminates breast cancer samples with different sensitivity to NACT.
The researchers presented the first version of the predictive panel in 2017. It included 12 genes. However, the main value of diagnosis is high accuracy with a relatively small number of biomarkers. The new panel includes only two genes. The diagnostic accuracy of the classifier based on IRF4 and C1QL2 genes methylation is 0.75, with sensitivity of 75% and specificity of 75%.
This work is one of the first in the world. RNF grant #18-15-430 supported the study.
DNA methylation markers panel can improve prediction of response to neoadjuvant chemotherapy in luminal B breast cancer
Sigin, V. O., Kalinkin, A. I., Kuznetsova, E. B., Simonova, O. A., Chesnokova, G. G., Litviakov, N. V., Slonimskaya, E. M., Tsyganov, M. M., Ibragimova, M. K., Volodin, I. V., Vinogradov, I. I., Vinogradov, M. I., Vinogradov, I. Y., Kutsev, S. I., Strelnikov, V. V., Zaletaev, D. V., Tanas, A. S.
Scientific Reports volume 10, Article number: 9239 (2020);